The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).
Petros Grivas
No relevant relationships to disclose
David M. Nanus
Consultant or Advisory Role - Aventis; Sanofi
Walter Michael Stadler
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Stephanie Daignault
Research Funding - University of Michigan
Robert Dreicer
Consultant or Advisory Role - Boehringer Ingelheim; Endo Pharmaceuticals; Janssen Pharmaceutical ; Millennium; Sanofi
Manish Kohli
No relevant relationships to disclose
Daniel Peter Petrylak
Consultant or Advisory Role - Amgen; Bellicum Pharmaceuticals (U); Dendreon; Egenix; Ferring; GlaxoSmithKline; Johnson & Johnson; Millennium; Novartis; Pfizer
Research Funding - AstraZeneca; Boehringer Ingelheim; Celgene; Dendreon; GlaxoSmithKline; Pfizer; Rogesen ; Sanofi
David J. Vaughn
No relevant relationships to disclose
Kathryn A. Bylow
No relevant relationships to disclose
Arie S. Belldegrun
No relevant relationships to disclose
Joseph L. Sottnik
No relevant relationships to disclose
Evan T. Keller
No relevant relationships to disclose
David C. Smith
No relevant relationships to disclose
Maha Hussain
No relevant relationships to disclose